Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
May 16 2018 - 4:24PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check
one):
|
[ ]
Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR
[ ] Form N-CSR
|
For
Period Ended: March 31, 2018
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For
the Transition Period Ended: ______________________________________________________________
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
OncBioMune
Pharmaceuticals, Inc.
Full
Name of Registrant
Former
Name if Applicable
11441
Industriplex Blvd., Suite 190
Address
of Principal Executive Office
(Street and Number)
Baton
Rouge, LA 70809
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR,
or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be
filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof,
could not be filed within the prescribed time period.
The
Company has encountered a delay in assembling the information, in particular its financial statements for the quarter ended March
31, 2018, required to be included in its March 31, 2018 Form 10-Q Quarterly Report. The Company expects to file its March 31,
2018 Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission within 5 calendar days of the prescribed due
date.
PART
IV — OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
Avital
Perlman
|
|
212
|
|
930
9700
|
Will
Rao
|
|
212
|
|
930
9700
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed ? If answer is no, identify report(s). Yes [ ] No [X]
Annual
Report on Form 10-K for the fiscal year ended December 31, 2017.
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof ?
Yes
[X] No [ ]
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
The
Registrant anticipates that there may be a fluctuation in derivative expense which may cause a significant change in results of
operations. The Registrant is currently calculating this effect and a reasonable estimate of such change cannot be made as of
the date of this filing.
OncBioMune
Pharmaceuticals, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
|
OncBioMune
Pharmaceuticals, Inc.
|
|
|
|
Date: May 16, 2018
|
By:
|
/s/
Jonathan F. Head
|
|
|
Jonathan
F. Head
|
|
|
Chief
Executive Officer
|